HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Case Against Perrigo Contests Pre-Emption Of Private Label OTC Liability

This article was originally published in The Tan Sheet

You may also be interested in...

FDA Regulation Of Homeopathics Does Not Pre-empt Damages Claims – Court

A federal judge rejected an argument that FDA’s regulation of homeopathic drugs pre-empts a state consumer protection law.

Generic Firms Get Supreme Shield From Product Liability, But Court Hints At Reg Change

In Pliva v. Mensing, the high court said it was impossible for generic manufacturers to comply with both state tort laws and FDA regulations requiring them to have the same labels as those for brand name counterparts.

Judge Returns Motrin Suit To Trial Court, Reject's J&J's Motion To Dismiss

A California state appeals court rejected Johnson & Johnson's motion to dismiss a claim alleging the firm was negligent for not providing specific warnings about Stevens-Johnson Syndrome on Motrin labels.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts